Concepedia

Pd-l1 Blockade

PD-L1 Blockade is a therapeutic strategy in cancer immunotherapy that inhibits the interaction between programmed death-ligand 1 (PD-L1) and its receptor PD-1 on T cells, thereby preventing tumor-induced immune suppression and enhancing anti-tumor immune responses.

6.4K

Publications

613K

Citations

46.8K

Authors

5.4K

Institutions

Publications per year

2017–2026

5.4K

Parents

Publications

6.4K

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

, , +17

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Roy S. Herbst, Dong‐Wan Kim, Enriqueta Felip et al. · The Lancet · 2015 · 6.5K citations

, , +14

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text

, , +17

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Sanjeev Mariathasan, Shannon J. Turley, Dorothee Nickles et al. · Nature · 2018 · 5.5K citations

, , +16

1–5 of 6.4K

Authors

46.8K

  1. GJ
    Gordon J. Freeman

    Dana-Farber Cancer Institute, United States

    80 publications · 24.6K citations

    65

    h-index

  2. FS
    F. Stephen Hodi

    Dana-Farber Cancer Institute, United States

    55 publications · 15.6K citations

    42

    h-index

  3. MD
    Matthew D. Hellmann

    Memorial Sloan Kettering Cancer Center, United States

    50 publications · 27.9K citations

    35

    h-index

  4. JM
    Janis M. Taube

    Johns Hopkins University, United States

    38 publications · 12.8K citations

    32

    h-index

  5. SA
    Scott Antonia

    Moffitt Cancer Center, United States

    43 publications · 4.6K citations

    30

    h-index

1–5 of 46.8K

Institutions

5.4K

  1. Dana-Farber Cancer Institute

    Boston, United States

    121 h-index

    1.5K publications

    363.1K citations

  2. Harvard University

    Cambridge, United States

    102 h-index

    1.1K publications

    309.7K citations

  3. The University of Texas MD Anderson Cancer Center

    Houston, United States

    102 h-index

    2K publications

    425.4K citations

  4. Memorial Sloan Kettering Cancer Center

    New York, United States

    91 h-index

    949 publications

    189.4K citations

  5. Institut Gustave Roussy

    Villejuif, France

    83 h-index

    873 publications

    343.3K citations

  6. Brigham and Women's Hospital

    Boston, United States

    79 h-index

    564 publications

    161.9K citations

  7. Yale University

    New Haven, United States

    79 h-index

    516 publications

    101.3K citations

  8. Inserm

    Paris, France

    79 h-index

    964 publications

    273.7K citations

1–8 of 5.4K

Venues

  1. Journal of Clinical Oncology

    604 publications · 45.2K citations

    91

    h-index

  2. Clinical Cancer Research

    164 publications · 30.8K citations

    87

    h-index

  3. Journal for ImmunoTherapy of Cancer

    JITC · 241 publications · 18.9K citations

    77

    h-index

  4. Nature Communications

    104 publications · 18.3K citations

    69

    h-index

  5. Cancer Immunology Research

    111 publications · 16.5K citations

    67

    h-index

1–5